Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Exelixis, Inc. (EXEL) Guidance & Earnings Results

On 2026-01-12 Exelixis, Inc. raised guidance: "FY2026 net product revenues guidance $2.325B-$2.425B vs FY2025…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-07-03 · read by EquiReason

EXELExelixis, Inc.Follow EXEL — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
16.0B
P/E TTM
20.3
Dividend yield
—
52-week
—
Next earnings
29 Oct, in 5 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
12 Jan 26RaisedFY2026 net product revenues guidance $2.325B-$2.425B vs FY2025 ~$2.123B
28 Jul 25ReaffirmedFY2025 total revenues $2.25-2.35B; net product revenues $2.05-2.15B; R&D $925-975M; SG&A $475-525M; effective tax rate 21-23% · full year

Exelixis, Inc. — questions

What guidance did Exelixis, Inc. give?
On 2026-01-12: "FY2026 net product revenues guidance $2.325B-$2.425B vs FY2025 ~$2.123B"
When does Exelixis, Inc. report earnings?
Exelixis, Inc.'s next earnings report is expected on 2026-10-29.

Every figure on this page comes from Exelixis, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.